Oculis Holding AG (OCS) Liabilities and Shareholders Equity (2021 - 2026)
Oculis Holding AG (OCS) posted quarterly Liabilities and Shareholders Equity of $311.6 million for Q1 2026, up 37.21% year-over-year from $227.1 million in Q1 2025, and up 5.54% quarter-over-quarter from $295.2 million in Q4 2025.
Oculis Holding AG (OCS) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends
Oculis Holding AG's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $311.6 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 37.21% year-over-year to $311.6 million; the TTM figure through Mar 2026 stood at $1.0 billion (up 56.29% YoY), while the FY2025 annual figure was $284.6 million, up 108.03% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $311.6 million, up from $295.2 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $311.6 million in Q1 2026, with the low at $38.5 million in Q4 2022.
- The 5-year median for Liabilities and Shareholders Equity is $150.0 million (2023), against an average of $175.0 million.
- The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity plunged 38.89% in 2022, then soared 235.12% in 2023.
- Oculis Holding AG's Liabilities and Shareholders Equity stood at $38.5 million in 2022, then jumped by 235.12% to $128.9 million in 2023, then grew by 6.57% to $137.4 million in 2024, then jumped by 114.89% to $295.2 million in 2025, then advanced by 5.54% to $311.6 million in 2026.
- Business Quant data shows OCS's Liabilities and Shareholders Equity at $311.6 million in Q1 2026, $295.2 million in Q4 2025, and $209.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - | 316.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 316.73 Mn |
| Mar 31, 2026 | 311.58 Mn |
| Dec 31, 2025 | 295.23 Mn |
| Sep 30, 2025 | 209.81 Mn |
| Jun 30, 2025 | 219.38 Mn |
| Mar 31, 2025 | 227.09 Mn |
| Dec 31, 2024 | 137.39 Mn |
| Sep 30, 2024 | 144.98 Mn |
| Jun 30, 2024 | 153.41 Mn |
| Mar 31, 2024 | 113.09 Mn |
| Dec 31, 2023 | 128.92 Mn |
| Sep 30, 2023 | 145.98 Mn |
| Jun 30, 2023 | 149.97 Mn |
| Dec 31, 2022 | 38.47 Mn |
| Dec 31, 2021 | 62.95 Mn |